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Activation of hepatic stellate cells (HSCs) is a critical step in
the development of liver fibrosis. During activation, HSCs lose
their lipid droplets (LDs) containing triacylglycerols (TAGs),
cholesteryl esters, and retinyl esters (REs). We previously pro-
vided evidence for the presence of two distinct LD pools, a pre-
existing and a dynamic LD pool. Here we investigate the mech-
anisms of neutral lipid metabolism in the preexisting LD pool.
To investigate the involvement of lysosomal degradation of neu-
tral lipids, we studied the effect of lalistat, a specific lysosomal
acid lipase (LAL/Lipa) inhibitor on LD degradation in HSCs
during activation in vitro. TheLAL inhibitor increased the levels
of TAG, cholesteryl ester, and RE in both rat and mouse HSCs.
Lalistat was less potent in inhibiting the degradation of newly
synthesized TAG species as compared with a more general
lipase inhibitor orlistat. Lalistat also induced the presence of
RE-containing LDs in an acidic compartment. However, tar-
geted deletion of the Lipa gene inmice decreased the liver levels
of RE, most likely as the result of a gradual disappearance of
HSCs in livers of Lipa/ mice. Lalistat partially inhibited the
induction of activationmarker-smoothmuscle actin (-SMA)
in rat and mouse HSCs. Our data suggest that LAL/Lipa is
involved in the degradation of a specific preexisting pool of LDs
and that inhibition of this pathway attenuates HSC activation.
The majority of vitamin A (retinol) is stored as retinyl esters
(REs)2 in specific liver cells, the so-called hepatic stellate cells
(HSCs) (1, 2). HSCs are located in the spaces of Disse, between
sinusoidal endothelial cells and hepatocytes. In a healthy liver,
HSCs contain large lipid droplets filled with REs, triacylglycer-
ols (TAGs), and cholesteryl esters (CEs). After liver injury, qui-
escent HSCs can transdifferentiate into activated cells with a
myofibroblastic phenotype (1). Activated macrophages in con-
cert with HSCs may initiate this transition by secreting cyto-
kines such as transforming growth factor  (TGF-), which
stimulate the synthesis of matrix proteins and the release of
retinoids by HSCs (1, 3). The loss of retinoids is associated
with a gradual disappearance of LDs in HSCs. We previously
reported that LD degradation in activated rat HSCs occurs in
two phases (4). Upon activation of HSCs, the LDs reduce in
size but increase in number during the first 7 days in culture.
In the second phase the lipid droplets disappear. Raman and
lipidomic studies showed that in the initial phase of HSC
activation, the REs disappear rapidly, whereas the TAG con-
tent transiently increases (4). This increase in TAGs in rat
HSCs is predominantly caused by a large and specific
increase in polyunsaturated fatty acid (PUFA)-containing
triacylglycerol species during the first 7 days in culture,
mediated by the increase in the ratio of the PUFA-specific
fatty acid CoA synthase 4 (ACSL4) to the nonspecific ASCLs,
especially ASCL1 (5).
The observed increase in the number of LDs during the first
phase of HSC activation can in principle be accomplished by
the de novo synthesis of the new LDs (6) or fission of existing
large LDs (7). We previously suggested that HSCs contain two
pools of LDs, a preexisting and a dynamic pool of LDs. The
preexisting LD pool is characterized by a larger average size of
the LDdiameter, the presence of REs, and the involvement of its
synthesizing enzyme LRAT (8, 9). The dynamic LDs were
shown to be smaller than preexisting LDs and have a dynamic
lipid metabolism, with new TAG synthesis and hydrolysis at
relatively high rates (9). We previously demonstrated that the
observed increase in number of LDs during the first phase of
HSC activation is likely the result of a decrease of the preexist-
ing pool of LDs and concomitant presence of a highly dynamic
pool of lipid droplets. In the dynamic LD pool, DGAT1 and
ATGL (also known as PNPLA2) are involved in the synthesis
and breakdown of newly synthesized TAGs, respectively (9).
The degradation pathway of the dynamic LD pool resembles
the well known mechanism of LD breakdown in adipose cells.
In these cells key roles were assigned to ATGL, its co-activator
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CGI-58, and hormone-sensitive lipase (10). The first two pro-
teins are known to have a more general function as deficiencies
in either one leads to neutral lipid storage diseases (11). Rat
HSCs were shown to express ATGL but not hormone-sensitive
lipase (9, 12).
In mouse and rat HSCs, ATGL was found to be involved
specifically in breakdown of newly synthesized TAGs but not in
degrading TAGs in the preexisting LD pool. This suggests the
existence of another lipolysis pathway (9). InmouseHSCs, lipid
breakdown was shown to be partially mediated by a lipophagic
pathway, as inhibition of autophagy increased the amount of
LDs (13–15). Because inhibition of autophagy was shown to
impair HSC activation in mice and this effect could be partially
reversed by the addition of exogenous FAs, it was suggested that
LDbreakdown is required to fulfill the energy demands ofHSCs
during activation (14).
The lipase active in lipophagy is thought to be lysosomal acid
lipase (LAL), which is encoded by the Lipa gene (16) and which
is also responsible for the degradation of lipoprotein derived
CEs and TAGs taken up by endocytosis (17). Targeted deletion
of Lipa in mice leads to severe CE and TAG accumulation in
hepatocytes (18), and LAL deficiency in humans results in
either Wolman disease or its milder variant, cholesteryl ester
storage disease (CESD), depending on the mutation in the Lipa
gene (19).
In this studywe addressed the question of whether inhibition
of LAL affects lipid metabolism in HSCs and the activation
process in rat and mouse HSCs. We, therefore, studied the
effect of the LAL-specific inhibitor lalistat (20–22) on HSC
lipid metabolism and activation, and we made use of a knock-
out strain of mice deficient in LAL.
Results
Neutral lipid breakdown in HSCs by lysosomal acidic lipase
The contribution of LAL/Lipa to neutral lipid breakdown
was studied by incubating rat HSCs with the LAL-specific
inhibitor lalistat (100 M) during the early activating phase
(days 1–7). As shown in Fig. 1A, lalistat caused a 3–4-fold
increase in the levels of all neutral lipids including TAGs, CEs,
and REs. Lalistat (100 M) proved to be non-toxic to the HSCs,
as the 6-day incubation had no effect on cell viability (98 13%
of control viable cells). The increase in TAGs and CEs could be
(partially) the result of uptake of exogenous lipids, e.g. as lipo-
proteins, from the medium that are also degraded by LAL. To
determine whether the observed increase in neutral lipids dur-
ing HSC activation by lalistat resulted from inhibition of break-
down of extracellular or intracellular neutral lipids, we limited
the contribution of exogenous lipids during the inhibitor treat-
ment by culturing the cells in medium with delipidated serum.
Under these conditions the levels of TAG species containing
PUFAs and the levels of CEs were much lower (Fig. 1B), in line
with the notion that PUFA-TAGs are synthesized from exoge-
nous PUFAs (5) and that CEs are derived from lipoproteins
from the medium. The levels of non-PUFA TAGs were less
affected by growing the HSCs in delipidated medium. Never-
theless, the levels of these non-PUFA TAGs and REs were
increased by lalistat to similar levels when compared with cells
grown in normal medium (cf. Fig. 1, A and B). During the incu-
bation with delipidated medium, TAGs might still be (re)syn-
thesized from endogenous FAs, derived from TAG and phos-
pholipid breakdown. We, therefore, also studied the effect of
lalistat in delipidated medium and in the presence of T863, a
DGAT1 inhibitor that was shown to inhibit TAG synthesis in
rat HSCs for 80% (9). When re-synthesis is inhibited, the
amount of non-PUFA TAGs is almost halved during the 3-day
incubation, similar to the60% decrease in RE levels (Fig. 1C).
Lalistat completely prevented the degradation of these lipids,
clearly indicating that this LAL inhibitor prevented the break-
down of preexisting lipids. To determine the specificity of lal-
istat, we tested the pyrazole-methanone compounds E4, F2,
and H4, which have been described to inhibit LAL (23). As
shown in Fig. 1D, the potency of the compounds to increase the
level of CEs, a clear hallmark of LAL-inhibition (18), was corre-
lated to their capacity to increase the levels of TAGs and REs.
The lalistat-induced accumulation of non-PUFA TAGs and
REs is opposite from our previous observation that HSCs from
ATGL-deficient mice accumulated PUFA-TAGs but not non-
PUFA TAGs and REs (9). As ATGL is involved in the turnover
of lipids in the dynamic LD pool (9), our combined results indi-
cate that Lalistat does not affect the dynamic LD pool but,
rather, the preexisting LD pool.
The dynamic LD pool can be readily labeled by the addition
of deuterated fatty acids to themedium resulting in rapid incor-
poration of the stable isotope in this pool of lipids (9). To inves-
tigate directly whether the LAL inhibitor could inhibit the
dynamic TAG pool, we labeled freshly isolated rat HSCs for 2
days with 25 M D4-palmitate in medium containing 10% fetal
bovine serum followed by a 2-day chase without stable isotope-
labeled palmitate but in the presence of lalistat or orlistat, a
general lipase inhibitor formerly known as tetrahydrolipstatin
(20, 24). As shown in Fig. 2A, a large percentage of TAGs can be
labeled with D4-palmitate. In the absence of inhibitors, the
doubly labeled TAG species are almost completely degraded
during the 2-day chase (Fig. 2, A and B). The general lipase
inhibitor orlistat could inhibit the degradation of the newly
madeTAGs almost completely. However, lalistat did not signif-
icantly affect the degradation of the labeled TAGs. Both lalistat
and orlistat increased the amount of unlabeled TAGs during
the chase to a similar level (Fig. 2). This suggests that lalistat
preferentially inhibits the degradation of a pool of unlabeled
TAGs, whereas orlistat affects the breakdown of both a pool of
labeled (i.e. newly synthesized) and unlabeled (preexisting)
TAGs.
Lalistat affected LDmorphology and localization
The observed lalistat-induced increase of a specific pool of
neutral lipids might lead to changes in LD size and/or number.
Examination of lipid droplet morphology in HSCs by fluores-
cence microscopy showed that lalistat induces an increase in
the number, but not in the size of the of LDs, whereas orlistat
increased both parameters, resulting in a specific increase in
big LDs (2 m) (Fig. 3). These data are in agreement with
the fact that these drugs affect different lipid breakdown
pathways. To verify that lalistat inhibits lipid breakdown in
the lysosomal compartment, we imaged LDs in HSCs after
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staining the acidic compartments with Lysotracker red (Fig.
4). In control cells we observed that20% of the Lysotracker
positive structures were close to RE-containing LDs, but
colocalization was not observed. Only in the HSCs incubated
with lalistat did we detect a consistent colocalization of these
structures, indicating that the lipids accumulated inside
lysosomes (Fig. 4 and supplemental Fig. S1). After incubation
with lalistat we also noticed HSCs that clearly contained two
populations of LDs, one that contained retinoids (UV auto-
fluorescent), and one that did not (Fig. 4A and supplemental
Fig. S1). Typically, the latter population was localized at the
periphery of the cell, whereas the former was present around
the nucleus together with the Lysotracker red-positive
structures.
Figure 1. The lysosomal lipase inhibitor lalistat increased the levels of neutral lipids in rat HSCs. A and B, isolated rat HSCswere incubated fromday 1 to
day7 inmediumwith10%FBS (A) or 10%delipidatedFBS (delip) (B) containingvehicle (DMSO)or 100M lalistat (lalist).C, isolated ratHSCswere incubated from
day 1 to day 4 in medium with delipidated FBS and 10 M DGAT1 inhibitor T863 additionally containing vehicle (DMSO; T863; white bars) or 100 M lalistat
(T863lalist; gray bars). D, isolated rat HSCs were incubated from day 1 to day 7 in medium with 10% FBS containing vehicle (DMSO) or 10 M pyrazole-
methanone compounds E4, F2, or H4. Subsequently, neutral lipids were determined by HPLC-MS. The values were normalized to the amount of cholesterol in
the sample and expressed relative to the level of the respective lipids present in the control cells incubated with FBS at day 7 (A, B, andD) or to the level of the
respective lipids present in the cells at day 1 (C). Data are themeans S.E. of 6 experiments performed in duplicate (A) or themeans S.D. of 3 (B and D) or 4
(C) experiments performed in duplicate. *, p 0.05, t test versus control.
Lysosomal acid lipase in lipid droplet metabolism
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Retinyl ester breakdown in HSCs by lysosomal acidic lipase
The observed inhibitory effect of lalistat on RE degradation
and accumulation of REs in lysosomes suggests that the Lipa
gene product has RE hydrolytic (REH) activity. Previously, an
acidic REH has been described that was different from LAL/
Lipa as judged from its insensitivity to bivalent metal ions like
Figure 2. Lalistat did not affect the degradation on newly synthesized TAG species in rat HSCs. Primary rat HSCs were incubated on day 1 with 25 M
D4-palmitate for 48 h. At day 3, part of the cells were harvested (pulse), and the remainingHSCswere chased for 48 hwith normalmediumwith vehicle (DMSO;
control), 100 M lalistat (lalist), or 40 M orlistat (orlist) and harvested at day 5 (chase). A, single or double deuterium-labeled (gray and dark gray bars) and
non-labeled (white bars) TAG fragments with two palmitoyl chains (16:0,16:0,x) were quantitated and expressed as the percentage of all TAG species. B shows
breakdown of TAG species from panel A, as the levels of the indicated TAG fragments at day 5, after the chase, were expressed relative to the level of the same
TAG species at thebeginningof the chase at day 3. Data are themeans S.D. of five experiments performed induplicate. *,p 0.05paired t test versus control.
Figure 3. Effect of lalistat and orlistat on LDmorphology and on the activationmarker-SMA in rat HSCs. A, confocal images of HSCs isolated from rats
incubated fromday1 today 7with vehicle (day 7), 100M lalistat, or 40Morlistat. Lipiddropletswere stainedwith LD540dye (green) and anti-SMAantibody
(red), andnucleiwere stainedwithHoechst (blue). In the first panel the redchannelwasomitted forbetter visibility of the LDs. Shownare representativepictures
from four experiments. B–D, images were analyzedwith CellProfiler v2.1.1. B, LD size was expressed in diameter (nm). C, LD numbers were expressed as a ratio
of scored lipid droplets and scored nuclei per image. D, LDs distribution is expressed as percentage of LDs with the specified size (in m). Image analysis was
based on at least 50 cells and 3000 lipid droplets per condition. Data are the means S.D. *, p 0.05 t test versus control.
Lysosomal acid lipase in lipid droplet metabolism
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Ca2 andMg2 (25, 26). We also found that the main REH in a
homogenate of ratHSCs and rat hepatocytes has an optimumat
pH 4 (Fig. 5, A and B). However, we could not observe a differ-
ence in inhibition by bivalent cations between the REH in com-
parison to the CE hydrolase activity, assayed simultaneously
(Fig. 5B). We also found that both activities were inhibited by
lalistat (Fig. 5B), with a similar IC501–3M. Furthermore, the
acidic REH activity was absent in liver homogenates from
Lipa/ mice and could be induced in CHO homogenates by
transfecting the CHO cells with recombinant rat Lipa (Fig. 5, C
and D). These latter experiments clearly show that Lipa has
REH activity in vitro.
To investigate the effect of Lipa on RE metabolism in HSCs,
we attempted to isolate HSCs from Lipa/ mice. However,
isolation of Lipa/ HSCs was not possible, most likely due to
the massive accumulation of lipids in the Lipa/ livers (18).
Therefore, we analyzed the RE content in livers of Lipa-defi-
cient and correspondingWTmice. Surprisingly, we found that
despite the 100-fold higher levels of CEs (Fig. 6A), the levels of
the REs were similar (retinyl stearate) or lower (retinyl palmi-
tate and retinyl oleate) in the livers of 7-week-old Lipa/mice
(Fig. 6B). In older mice (4–5 months; average 20 weeks), the
difference between theWTand the Lipa-deficientmice became
even larger, as theWTmice continued to accumulate REs, and
the Lipa/mice lost most of their REs (Fig. 6B). The low levels
of REs in the livers of the 4–5-month-old Lipa/ mice were
accompanied by a decrease in the expression of LRAT mRNA,
considered a marker for quiescent HSCs (27), but not by an
up-regulation of the HSC activation marker -smooth muscle
actin (-SMA; Fig. 6, C and D). This suggests that the livers of
the Lipa/mice gradually lose their HSCs.
To exclude that the apparent discrepancy between the lack of
effect of Lipa knock out in mice in vivo on RE storage and the
observed effect of the Lipa-inhibitor lalistat on RE levels in rat
HSCs in vitro is caused by species differences between rat and
mouse, we compared the effect of lalistat on neutral lipid levels
in primary mouse HSCs with its effect on rat HSCs (cf. Figs. 7
and 1A). The levels of REs in primary isolated mouse HSCs at
day 1 (5.5  3 nmol of RE/mg of protein) were found to be
similar to that in rat HSCs (6  4 nmol of RE/mg of protein).
We found that lalistat also caused an increase in TAGs, CEs,
and REs in mouse HSCs. In comparison to rat HSCs, the lal-
Figure4. Lalistat increasedcolocalizationofLDandthe lysosomal compartment in ratHSCs.A, confocal imagesofHSCs isolated fromrats incubated from
day 1 to day 4 in medium with 10% FBS in the presence of vehicle (control) or 100 M lalistat. Live HSCs were stained with Lysotracker Red DND99 (red) and
Bodipy (LD dye, green) for 30min before imaging. Blue is the UV autofluorescence signal from REs. In the boxes higher magnification of the separate channels
and the merge are shown. The white bar is 10 m. B, UV-positive LDs were counted and classified manually. Classifications were (i) not in contact with
Lysotracker red structures, (ii) in contact or surrounded by Lysotracker red structures (Lysotr.-associated;white bars) or completely colocalizedwith Lysotracker
red structures (Lysotr.-colocalized; gray bars). Image analysiswas basedon 40 cells from4 independent experiments. Data are themeans S.E. *, p 0.05, t test
versus control.
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istat-induced increase in RE level in mouse was somewhat
lower (2.5-fold versus almost 4-fold in rat HSCs).
Rat HSCs have an active autophagy pathway that is required
for cell survival
Determination of LipamRNAexpression in quiescent (day 1)
and activated (day 7) rat HSCs shows that Lipa mRNA is up-
regulated during activation in vitro (Fig. 8A). Endogenous neu-
tral lipids are thought to traffic to the lysosomal compartment
by the autophagy pathway. An active autophagy pathway has
indeed been described in activated mouse HSCs (13–15). To
investigate the involvement of the autophagy pathway in rat
HSCs, we made use of the autophagy marker protein LC3B,
which can be detected as two isoforms; one represents the cyto-
solic LC3B-I and the other one represents LC3B-II, which is
conjugated with phosphatidylethanolamine and is present on
autophagosomes. The amount of LC3B-II is closely related to
the autophagosome number and is a good indicator for activa-
tion of the autophagy pathway (28). Primary rat HSCs have a
high ratio of the lipidated to unlipidated form of the autophagy
protein LC3B already at day 1 and which continues until day 7
(Fig. 8B). As a control, the presence of LC3B-I and LC3B-II in
LX-2 cells is shown. LX-2 cells are the humanHSC cell linewith
a mixed phenotype with characteristics that resemble both the
quiescent and activated phenotype (29). LX-2 cells have a low
lipidated to unlipidated ratio that changes upon stimulation of
the autophagy pathway (Fig. 8B). Autophagy was also detected
in rat HSCs by Cyto-ID staining (supplemental Fig. S2). Cyto-
ID-positive structures and lipid droplets are abundantly pres-
ent in HSCs at day 3, but only in the presence of lalistat colo-
calization of these structures is observed.
To study the contribution of the autophagy pathway in LD
breakdown, we attempted to inhibit this pathway with specific
inhibitors including 3-methyladenine (5 mM) and bafilomycin
A1 (7.5 nM) and with the inhibitor of lysosomal degradation
chloroquine (5 M). All these inhibitors caused massive death
of the rat HSCs within 12 h, although the doses used did not
affect the viability of the human stellate cell line LX-2 (results
Figure 5. LAL/Lipa had retinyl esterase activity in vitro. REHwas assayed with RP presented in liposomes as substrate in a buffer with pH 7, pH 4, and pH 4
containing 10 M lalistat or pH4 containing 10 mm MgCl2 in homogenates of primary rat HSCs cultured for 4 days (16 g of protein) (A), freshly isolated rat
hepatocytes (400g of protein) (B), wholemouse livers (400g of protein) (C), or cultured CHO cells 1 day after transfection with an empty expression vector
or with an expression vector containing rat Lipa cDNA (40g of protein) (D). In B, cholesterol esterase activity (CEH) was assayedwith D7-cholesterol oleate as
substrate presented in liposomes together with RP. Free retinol, RP, D7-cholesterol, and D7-CE levels were quantitated by HPLC-MS in theMRMmode. Retinol
and D7-cholesterol are expressed relative to the levels of their respective esters present at the start of the incubation. Data are the means  S.D. of three
experiments performed in duplicate.
Lysosomal acid lipase in lipid droplet metabolism
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not shown). When we studied the autophagy inhibitors in rat
HSCs at lower concentrations that were tolerated, we could not
find an effect of these inhibitors on autophagy or lysosomal
acidification as analyzed with the LC3B-I to -II ratio and imag-
ing with Lysotracker red (results not shown). From these data
we conclude that rat HSCs in culture have a very active
autophagy pathway, already as early as day 1 after isolation. The
ratio of lipidated to unlipidated LC3B is markedly lower in
mouse HSCs (13, 14), and this may explain the high sensitivity
of rat HSCs toward autophagy inhibitors, as autophagy seems
more essential for rat HSCs as compared with mouse HSCs, at
least under our culture conditions.
We considered the possibility that the essential role of
autophagy in rat HSCs is the result of an essential reutilization
of nutrients from the autophagy pathway. A highly active
autophagy pathway in rat HSCs may, therefore, suggest an
active turnover of the preexisting LD pool. To study this in
more detail, we took advantage of the RE metabolism in HSCs.
We previously showed that retinol is generated from hydrolysis
of endogenous REs and is available for re-synthesis of REs
in either the preexisting (LRAT-mediated) or dynamic pool
(DGAT1-mediated) of LDs (8). Indeed, after the addition of
deuterated fatty acids to the cell culture medium, we not only
observed an incorporation of D4-labeled palmitate into TAGs
(Fig. 2) but also a significant D4-labeling of retinyl palmitate
(RP) (30%) (Fig. 8C). This indicates that a significant part of
the retinyl palmitate is re-synthesized fromendogenous retinol,
derived from the breakdownof endogenousREs, as themedium
Figure 6. Retinyl esters did not accumulate in livers of LAL-deficientmice. Liverswere obtained fromeitherWT and Lipa/mice at an age of 7weeks (wk)
or between 4 and 5 months (20 weeks). A and B, CEs (panel A) and REs (panel B) were quantitated by HPLC-MS in the MRM mode. The following REs were
analyzed: RP (gray bars), retinyl stearate (RS; dark gray bars), and retinyl oleate (RO; white bars). C and D, the relative mRNA expression of LRAT (a marker for
quiescentHSCs;panel C) and-SMA (HSCactivationmarker;panelD)wasmeasuredbyqPCR.Data are themeansS.D. of 5mice (20weeks) or 4mice (7weeks),
assayed in duplicate. *, p 0.05 t test versusWT.
Lysosomal acid lipase in lipid droplet metabolism
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contained almost no retinol nor REs (results not shown). In line
with this, we found that lalistat, which was shown to inhibit the
breakdown of the existing REs (Fig. 1) and thus expected to
prevent the release of free retinol, clearly prevented the incor-
poration of D4-palmitate into REs (Fig. 8C).
The RE species distribution changes during HSC activation.
In quiescent HSCs, retinyl palmitate is the predominant RE
species (80%) in preexisting LDs (8). Upon activation, the
percentage of retinyl palmitate species drops, reflecting RE syn-
thesis by DGAT1 in the dynamic LD pool. If lalistat inhibits the
breakdown of REs from the preexisting LD pool, then it is
expected that lalistat also prevents the remodeling of the RE
pool during activation as reflected in the change in retinyl ester
species distribution (8). Indeed, at day 1 the predominantly reti-
nyl ester is palmitate (84  3%) in rat HSCs, whereas after
activation on day 7 a more diverse species distribution was
observed (Fig. 8D). In the presence of lalistat, the species distri-
bution at day 7 more resembled that on day 1 with 74  4%
retinyl palmitate.
Lalistat inhibited HSC activation
To investigate whether the change in neutral lipid metabo-
lism by the LAL inhibitors or orlistat has an effect on the acti-
vation process, we determined the expression levels of -SMA.
-SMA is considered a marker for HSC activation and was
clearly up-regulated in mouse and rat HSCs at day 7 (9). We
observed a clear inhibition of the expression of -SMA by both
lalistat and orlistat in rat HSCs, both on protein and mRNA
levels (Figs. 3A and 9). The potency of the LAL inhibitors of the
class of pyrazole-methanone compounds, E4, F2, and H4, to
inhibit -SMA expression correlated with their potency to
inhibit neutral lipid degradation (cf. Fig. 1D and Fig. 9). In
mouse HSCs lalistat, but not orlistat, inhibited HSC activation
(Fig. 9). Orlistat was also less effective in mouse HSCs com-
pared with lalistat and compared with its effect in rat HSCs in
increasing the levels of TAGs, CEs, andREs (results not shown).
It has been reported that TAGdegradation is required for the
generation of FAs for energy during HSC activation in mouse
stellate cell line JS1 (14). We, therefore, tested whether FAs
derived from TAGs are required for the energy demand of rat
HSCs under our culture conditions by treating the cells with
etomoxir, an inhibitor of FA oxidation. However, we did not
observe an effect of this inhibitor on rat HSC activation (Fig. 9),
although the effectiveness of the drug was confirmed by the
observation of a 2-fold increase in TAG levels in the presence of
this FA oxidation-inhibitor (results not shown). Thus, we con-
sider it more likely that hydrolysis of a specific lalistat-sensitive
LD pool is involved in HSC activation for other reasons.
Discussion
We show here that lalistat, a specific inhibitor of the Lipa
gene product LAL, affects the levels of three subtypes of neutral
lipids, i.e. CEs, TAGs, and REs, in rat and mouse HSCs. The
lalistat-induced increase in CEs is in line with the established
function of LAL in degrading CEs from lipoproteins in the lys-
osome (18, 19). As expected, the increase was much lower in
medium depleted of lipoproteins. The residual increase in the
absence of exogenous lipoproteins may be caused by inhibiting
the degradation of CEs delivered to the lysosome by the
autophagy pathway, similarly to that described inmacrophages
(16, 30). Orlistat was less potent in comparison to lalistat in
inhibiting the breakdown of CEs, indicating that it inhibited
LAL to a lesser degree in HSCs at the concentration used.
LD pools
The comparison between the effects of the inhibitors lalistat
and orlistat on TAG levels clearly indicated the existence of
different pools of TAGs. Orlistat was more potent at inhibiting
the degradation of newly synthesized TAGs, as judged from its
large inhibitory effect on the breakdown of labeled TAGs. In
contrast, lalistat was more potent in inhibiting the preexisting
lipid pool as it did not inhibit the degradation of newly labeled
TAGs but prevented the breakdown of existing TAGs when
new TAG synthesis was blocked. We previously showed addi-
tional evidence for metabolically different TAG pools in HSCs
from studies with ATGL/ mice and the DGAT1 inhibitor
T863 (9). We reported that the TAG lipase ATGL specifically
targets newly synthesized PUFA-enriched TAGs, made prefer-
entially by DGAT1 in combination with ACSL4. These newly
formed TAGs are likely to form new LDs. By use of lalistat, we
now have unmasked two pools of LDs by live cell-imaging of rat
HSCs: one pool of LD-containing retinoids located predomi-
nately round the nucleus and a pool present in the periphery of
the HSCs that did not contain REs. The combined breakdown
of LDs in one place and re-synthesis in another would explain
our previous observations in activated rat HSCs, i.e. that LDs
reduce in size but increase in number and are localized in cel-
lular extensions (4). Considering that in activated rat HSCs all
LDs have a similar lipid spectrum containing a low amount of
REs (4), we have to assume that REs are incorporated in the new
LDs. Indeed, fromD4-palmitate labeling studies and RE species
Figure 7. Effect of lalistat on neutral lipid levels in mouse HSCs. Isolated
mouse HSCs were incubated from day 1 to day 7 in medium with 10% FBS
containing vehicle (DMSO; control) and 100M lalistat (Lalist). Subsequently,
neutral lipids were determined by HPLC-MS. The values were normalized to
the amount of cholesterol in the sample and expressed relative to the level of
the respective lipidspresent in the control cells at day7.Data are themeans
S.E. of six experiments performed in duplicate. *, p 0.05 t test versus control.
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distribution we have now evidence that REs, like TAGs, are
partly re-synthesized during activation (8).
The lipase inhibitors orlistat and lalistat also caused a differ-
ent effect on the morphology of the LDs. Lalistat increased the
number but not the size of the LDs, whereas orlistat and Atgl-
statin (9) also increased the size of the LDs. This suggests that
inhibition of lipase activity on the new LDs allow them to grow
beyond a certain limit maintained under normal conditions by
the consorted action of theTAGsynthesizing enzyme (presum-
ably DGAT1) and the TAG degrading activity (presumably
ATGL). In contrast, lalistat-mediated accumulation of LDs
reveals that the autophagy pathway engulfs lipid fragments
around 0.8 m, roughly similar to the size of the newly formed
LDs (Fig. 3). This would be compatible with the reported sizes
of autophagosomes ranging between 0.50 and 1.5 m (31, 32)
and with the observation in rat HSCs analyzed by EM that the
subpopulation of LDs that was surrounded by lysosomes was
smaller than the cytosolic LDs (33). A model of lipid metabo-
lism and the formation of the different LD pools in HSCs is
depicted in supplemental Fig. S3.
Lipa and retinyl ester hydrolysis
Besides inhibiting the degradation of CEs and TAGs, lalistat
proved to be a potent inhibitor of RE degradation. As we
observed REs in the acidic compartment after treatment with
lalistat, a lysosomal lipase is involved in the breakdownof REs in
activated HSCs. The most likely REH is Lipa/LAL as we found
that it has clear REH activity in vitro. These findings are in line
with similar results described recently by Grumet et al. (34).
The REs are most likely delivered to the lysosomes by the
autophagy pathway known to be active in activated HSCs (13–
15) (Fig. 8). Unfortunately, we could not assess the contribution
of the autophagy pathway in the degradation of REs by using
autophagy inhibitors, as these inhibitors affected the viability of
the primary rat and mouse HSCs under our conditions.
Figure 8. Expression of Lipa, activation of autophagy, and re-esterification of retinol in rat HSCs. A, relativemRNA expression of lysosomal acidic lipase
LAL/Lipa in quiescent (day 1; white bar) and activated (day 7; gray bar) rat HSCs was determined by qPCR. B, immunoblot probed with LC3B antibody of total
proteins (10g) of quiescent (day 1) and activated (day 7) rat HSCs and the human stellate cell line LX2 incubated for 4 h with vehicle (control), the autophagy
inducer rapamycin (200nM), or rapamycin in thepresenceof 20Mchloroquine (CQ) topreventbreakdownof LC3B in the lysosome. LC3B-I is thenon-activated
form, andLC3B-II is theactivated formcontaining the lipidphosphatidylethanolamine. Shown is a representativeblot fromthreeexperiments.CandD, primary
rat HSCs were either harvested at day 1 or incubated in medium with 10% FBS and 25 M D4-palmitate-containing vehicle (DMSO; control) or with 100 M
lalistat (Lalist) for 3 days (day 1 to day 4; C) or incubatedwithmediumwith 10% FBS containing vehicle (DMSO; control) or with 100M lalistat (Lalist) for 6 days
(day 1 to day 7; D). D4-labeled and non-labeled REs were quantitated by MRM. D4-labeled retinyl palmitate (D4-Palm) and non-labeled RP were expressed
relative to the total RP levels at day 1 (C), or specific RE species were expressed as a percentage of total REs (D). Data are themeans S.D. of three experiments
performed in duplicate. *, p 0.05 paired t test versus day 1 (A) or versus control (C and D).
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An additional non-Lipa/non-autophagy degradation path-
way for REs likely exists in mouse HSCs. RE levels in mouse
HSC drop by90% from day 1 to day 7 (9), implying that only
10% is left at day 7. The 2.5-fold increase seen in the presence of
lalistat indicates that still 75% of the RE pool has disappeared
from themouse HSCs in the presence of the LAL inhibitor. For
comparison, rat HSCs at day 7 still has 30–20% of the RE con-
tent of day 1 in the absence of lalistat (4) and retainmost of their
REs in the presence of this inhibitor. Preliminary microarray
data revealed that the expression of Lipa in mouse HSCs was
almost halved at day 7 compared with day 1, whereas we found
a 2-fold up-regulation in rat HSCs during activation (Fig. 8). A
number of neutral carboxyl esterases was found to have REH
activity, including ES4, ES10, and ES22 (35). The patatin-like
phospholipase domain-containing 3 (PNPLA3) protein was
also shown to have retinyl-palmitate lipase activity in human
hepatic stellate cells (36). However, the relative contribution of
any of these enzymes in RE degradation in HSCs upon activa-
tion is unknown.
Despite the capacity of LAL to degrade REs, no accumulation
of REs was found in livers from LAL-deficient mice as was
observed for CEs. In contrast, young (7-week-old mice)
Lipa/mice had even lower liver levels of REs compared with
WT mice, and livers of older mice (20 weeks) were almost
devoid of RE stores. Retinoid storage in the liver is thought to be
composed of multiple stages. Dietary retinoids are initially
packaged as REs in chylomicrons by intestinal cells. The chylo-
micron remnants are taken up by hepatocytes and degraded
in a supposedly non-lysosomal compartment (37). Subse-
quently, retinol is transferred from the hepatocytes to HSCs,
where it is esterified by LRAT and stored in LDs (35). The
lower storage of REs in the liver of the LAL-deficient mice
may, therefore, point at a role of LAL in RE degradation in
other cell types besides activated HSCs. The lower levels of
REs in the livers of the LAL-deficient mice were also recently
observed by Grumet et al. (34). They found a different reti-
noid handling in the intestine as a contributing factor to the
lower RE levels in the liver. Furthermore, the here-observed
role of LAL in degrading REs in activated HSCs, which have
an active autophagy pathway, may be less prominent in qui-
escent HSCs in a healthy liver.
LRAT expression, a marker for quiescent HSCs (27), was not
affected in the young Lipa/ mice but was lost in the older
mice, concomitant with a further loss in REs. This suggests that
the REs in the young mice are presumably stored predomi-
nantly in HSCs, as in the older mice REs stores were probably
decreased due to a loss of quiescent HSCs. The HSCs were not
yet fully activated in the 20-week-old Lipa/mice, aswe found
no up-regulation of the HSC activation marker -SMA. In ear-
lier studies on the Lipa/mice, it was described that in young
mice (1.5months) lipid (CE/TAG)was predominantly accumu-
lated in hepatocytes but that in older mice (5–8 months)
macrophages became the major lipid-storing cells (38). This
suggests that the influx of macrophages might be the cause of
the disappearance of quiescent HSCs in the 20-week-old
Lipa/ mice. The absence of quiescent HSCs is probably
followed by a fibrotic stage, as in older (24 weeks) Lipa-
deficient mice clear liver fibrosis was detected (39). Likewise
humans with mutations in Lipa are known to develop liver
fibrosis (19).
Lipa and HSC function
The effect of lalistat, the pyrazole-methanone compounds
E4, F2, andH4 and orlistat on lipid levels in rat andmouseHSCs
generally correlatedwith their effect onHSCactivation. Lalistat
increased all classes of neutral lipids in both rat and mouse
HSCs and attenuated activation in rat and mouse HSCs to a
similar, albeit relatively low degree (30–40%, Fig. 9). Orlistat
was more potent in rat HSCs as compared with mouse cells
both in increasing neutral lipid levels and preventing activation.
The inhibitory effect of lalistat and orlistat on rat HSC activa-
tion was comparable with the effect of another lipase inhibitor,
Atglistatin (9). In comparison with lalistat, Atglistatin is more
potent in inhibitingTAGbreakdownbut less potent in prevent-
ing RE and CE degradation. Although we cannot exclude the
possibility that these drugs affect HSCs activation by other,
non-lipid related pathways, their effects onHSC activation cor-
related with their effect on of neutral lipid breakdown. There-
fore, it seems that HSCs require an available TAG/RE pool for
optimal functioning. This pool may act as a buffer for FAs
required for energy (14) or synthesis ofmembranes or bioactive
lipids, like prostanoids. In rat HSCs we could not find evidence
for a requirement for FA as a source of energy, as the -oxida-
tion inhibitor etomoxir did not affect activation. Another pos-
sibility would be that the neutral lipids by their physical pres-
ence in the cytosol, interfere with the differentiation processes
needed for activation, like ER and Golgi expansion. This would
also explain that mouse HSCs containing almost no LDs by a
lack of LRAT show a normal activation response to liver injury
(27).
Figure9. Effectofalterations inneutral lipidmetabolismonactivationof
rat and mouse HSCs. Relative gene expression of -SMA (HSC activation
marker) was measured by qPCR. HSCs isolated from rats or mice were incu-
bated from day 1 to day 7 with vehicle (DMSO; control), 100M lalistat (lalist),
40Morlistat (orlist), 10Mpyrazole-methanone compounds E4, F2, or H4, or
50 M etomoxir. Relative mRNA levels of -SMA were expressed relative to
the levels in the control-treated cells (n 5 or n 3 in the case of E4, F2, and
H4). Data are the means S.D. *, p 0.05 t test versus control.
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Experimental procedures
Reagents
Lalistat (lalistat-2; 3,4-disubstituted thiadiazole carbamate,
compound 12 from Rosenbaum et al. (21), was a gift from Paul
Helquist (University of Notre Dame). The pyrazole-methanone
compounds E4, F2, and H4 were described in VanderVen et al.
(23). D4-palmitate and 3-methyladenine were purchased from
Cayman Chemical (Ann Arbor, MI). D7-cholesteryl palmitate
was from Avanti polar lipids. Dulbecco’s modified Eagle’s
medium (DMEM), fetal bovine serum (FBS), and penicillin/
streptomycin were obtained from Gibco. Bovine serum albu-
min (BSA) fraction V was obtained from PAA (Pasching,
Austria). T863, chloroquine diphosphate salt, bafilomycin A,
L--phosphatidylcholine, retinyl palmitate (RP), collagenase
(Clostridium histolyticum Type I), and basic chemicals were
obtained from Sigma. Themouse monoclonal antibody against
-SMA was from Thermo Scientific (Waltham, MA), and the
rabbit polyclonal antibody against LC3B was from Novus Bio-
logicals (Littleton, CO; catalog number NB600-1384). Lipid
droplet staining dye LD540was kindly donated byDr. C. Thiele,
University of Bonn, Bonn, Germany. Hoechst 33342 and HCS
LipidTOXTM Red neutral lipid stain were obtained from
Molecular Probes (Eugene, OR), and paraformaldehyde (PF)
(8%) was obtained from Electron Microscopy Sciences (Hat-
field, PA). FluorSave was purchased from Calbiochem, and all
HPLC-MS solvents were from Biosolve (Valkenswaard, The
Netherlands) with exception of chloroform (Carl Roth,
Karlsruhe, Germany) andwere ofHPLCgrade. Silica-G (0.063–
0.200 mm) was purchased from Merck. Delipidated FBS was
made from FBS by extraction with diisopropyl ether and n-bu-
tyl alcohol (FBS/diisopropyl ether/n-butyl alcohol, 10/8/4
v/v/v) followed by extensive dialysis against phosphate-buff-
ered saline (PBS) at 4 °C.
Animals
We used adult male Wistar rats (300–400 g) and 10–12-
week-old male and female C57BL/6J mice for HSC isolation.
Lipa/ mice were generated as described (18). Procedures of
rat and mouse care and handling were in accordance with gov-
ernmental and international guidelines on animal experimen-
tation and were approved by the Animal Experimentation
Committee (Dierexperimentencommissie; DEC) of Utrecht
University (DEC numbers 2010.III.09.110, 2012. III.10.100, and
2013.III.09.065).
HSC isolation and in vitro primary cell culture
Stellate cells were isolated from livers of rats and mice by
collagenase digestion followed by differential centrifugation
(40). After isolation, HSCs were plated in 24-, 12-, or 6-well
plates at a density of 2 	 104, 5 	 104, or 1 	 105 cells/well,
respectively. Cells were cultured in DMEM supplemented with
10% FBS, 100 units/ml penicillin, 100 g/ml streptomycin, and
4 l/ml Fungizone in a humidified 5% CO2 incubator at 37 °C
and were protected from light by covering with aluminum foil.
Medium was changed every 3 days. Cell viability and cytotox-
icity was assayed with the Cell Counting Kit-8 according to the
instructions provided by themanufacturer (DojindoMolecular
Technologies, Inc., Rockville, MD).
RNA isolation, cDNA synthesis, and quantitative PCR
Total RNA was isolated using the RNeasy Mini Kit (Qiagen,
Venlo, The Netherlands) including the optional on-column
DNase digestion (Qiagen RNase-free DNase kit). RNAwas dis-
solved in 30 l of RNase free water and quantified by a Nano-
drop ND-1000 (Isogen Life Science, IJsselstein, The Nether-
lands). An iScript cDNA Synthesis Kit (Bio-Rad) was used to
synthesize cDNA. Primer design and quantitative PCR (qPCR)
conditions were as described previously (41). Briefly, qPCR
reactions were performed in duplicate using a Bio-Rad detec-
tion system. Amplifications were carried out in a volume of 25
l containing 12.5 l of 2	SYBR Green supermix (Bio-Rad), 1
l of forward and reverse primer, and 1 l of cDNA. Cycling
conditions were as follows: initial denaturation at 95 °C for 3
min followed by 45 cycles of denaturation (95 °C for 10 s),
annealing (temperature as described in supplemental Table S1
or Tuohetahuntila et al. (9) for 30 s), and elongation (72 °C for
30 s). A melting curve analysis was performed for every reac-
tion. To determine relative expression of a gene, a 4-fold dilu-
tion series from a pool of all samples were used. IQ5 Real-Time
PCR detection system software (Bio-Rad) was used for data
analysis. Expression levels were normalized by using the aver-
age relative amount of reference genes. Reference genes used
for normalization were based on their stable expression in
stellate cells, namely, tyrosine 3-monooxygenase/tryptophan
5-monooxygenase activation protein, zeta (Ywhaz), hypoxan-
thine phosphoribosyltransferase (Hprt), and hydroxylmethyl-
bilane synthase (Hmbs). Primers of reference genes are as
described Tuohetahuntila et al. (9), and primers of target genes
are listed in supplemental Table S1.
Immunofluorescence
Freshly isolated HSCs grown on glass coverslips in 24-well
plates at 37 °C for 7 days were fixed in 4% (v/v) PF at room
temperature for 30 min and stored in 1% (v/v) PF at 4 °C for a
maximum of 1 week. Before staining, HSCs were washed twice
in PBS, permeabilized by saponin (0.1% (w/v); Riedel-de Haën,
Seelze, Germany), and blocked with 2% BSA in PBS for 1 h at
room temperature. After blocking, cells were incubated for 1 h
with the primary antibody against -SMA (50–75 g/ml),
washed again, and incubated for 1 hwith a fluorescently labeled
secondary antibody (15 g/ml) supplemented with Hoechst (4
g/ml) for nuclear counterstaining and lipid droplet dye LD540
(0.05 g/ml). Thereafter, coverslips were mounted with Fluor-
Save on microscopic slides, and image acquisition was per-
formed at the Center of Cellular Imaging, Faculty of Veterinary
Medicine, Utrecht University on a Leica TCS SPE-II confocal
microscope. Toquantify lipid droplet size andnumbers per cell,
confocal images of LD540 (lipid droplets) and Hoechst33342
(nuclei) were analyzed with CellProfiler v2.1.1. Recognized
lipid droplets and nuclei were overlaid on the original image to
confirm the identity. The error rate was5% for lipid droplets
and2% for nuclei.
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Live cell imaging
For live cell imaging, cells (20-l cell suspensions,2	 105
cells/ml) were plated on an 8-well glass-bottom slide from Ibidi
(Planegg/Martinsried, Germany). Cells were cultured under
similar conditions as described above in the presence or
absence of lalistat for 3 days. At the 4th day after isolation,
media were changed with fresh media 2 h before imaging. Just
before imaging lysosomes in combination with LDs, 100 l of
Lysotracker Red DND99 (Life Technologies, final concentra-
tion of 75 nM) and Bodipy 493/503 (Molecular Probes, final
concentration of 200 nM) were added for 30 min in the incuba-
tor. For detection of autophagy the Cyto-ID Autophagy
Detection Kit was used following the protocol supplied by the
manufacturer (Enzo Life Sciences, Inc. Farmingdale, NY) with
co-staining of the LDs with HCS LipidTOX™ Red neutral lipid.
Images of the samples were recorded using a NIKONA1R con-
focal microscope equippedwith a humidified imaging chamber
set to 5% CO2 and 37 °C (TOKAI hit, Japan) at the Center for
Cell Imaging (CCI), Faculty of Veterinary Medicine, Utrecht
University.
REH and cholesteryl esterase activity assay
REH was assayed essential as described (25). In short, an ali-
quot of homogenized mouse liver (400 g of protein), homog-
enized rat hepatocytes (400g of protein), or ratHSCs (16g of
protein) were incubated in 100 l of sodium citrate buffer (60
mM; pH4.1) orHEPESbuffer (60mM; pH7) at 37 °C in a shaking
water bath for 45 min in the presence of 1.9 mM RP and/or 1.5
mM D7-cholesteryl palmitate (D7-CE) incorporated into lipo-
somes. Liposomes were made by dissolving 20 mg of L--phos-
phatidylcholine and 0.5 mg of RP and/or 0.5 mg of D7-CE in
chloroform. After solvent evaporation, the lipids were sus-
pended in 1 ml of 50 mM NaCl and 10 mM Tris, pH 7.4, by
sonication and centrifuged at 17,300	 g for 10min to sediment
large vesicles. The reaction was stopped by the addition of 100
l of ethanol, and lipids were determined by HPLC-MS using
multiple reaction monitoring (MRM) (8).
Analysis of neutral lipids by HPLC-MS
Lipids were extracted from a total cell homogenate of HSCs
grown in a 12-well plate by the method of Bligh and Dyer (42)
after the addition of 200 pmol of tripentadecanoylglycerol as
the internal standard. Extracted lipids were separated in a neu-
tral and phospholipid fraction and analyzed on HPLC-MS as
described (9). In short, the neutral lipid fraction was reconsti-
tuted in methanol/chloroform (1/1, v/v) and separated on a
Kinetex/HALO C8-e column by a gradient of methanol/H2O
(5/5, v/v) to methanol/isopropyl alcohol (8/2, v/v). Mass spec-
trometry of neutral lipids (TAGs, CEs, REs, and cholesterol)
was performed using Atmospheric Pressure Chemical Ioniza-
tion (APCI) interface (AB Sciex Instruments, Toronto, ON,
Canada) on a Biosystems API-2000 Q-trap mass spectrometer.
The system was controlled by Analyst version 1.4.2 software
(MDS Sciex, Concord, ON, Canada) and operated in positive-
ion mode. TAG fragments with two non-, single-, and double-
labeled palmitoyl chains (16:0,16:0,x) were quantitated by
counting ions withm/z of 551, 555, and 559, respectively. Typ-
ical TAG species quantitated were: non PUFA, 52:3 (m/z 859)
and 54:3 (m/z 885); 1	PUFA, 56:5 (m/z 909) and 58:6 (m/z
935); 2	PUFA 60:9 (m/z 957) and 62:11 (m/z 981). For the
quantification of the various (deuterated) RE and CE species,
we used MRM in positive-ion mode by monitoring molecule
specific transitions as described (8). Specific transitions ana-
lyzed are summarized in supplemental Table S2. The quanti-
tated lipids were normalized to the amount of cholesterol or
protein in the same sample. Cholesterol was found to be a
good marker for both recovery and cellular material, as the
cholesterol/protein ratio was found to be constant during
HSC culture.
Statistical analysis
Each experiment was performed in duplicate and repeated at
least three times. Comparisons of a variable between two
groups were made with unpaired or paired Student’s t test
depending on whether the data were normalized to a control
before analysis. Differences were considered statistically signif-
icant for p values0.05.
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